The medical device firm cites new Medicare reimbursement codes as a key driver for revenue growth in 2026.
Myomo Inc. projected second-quarter revenue of $10.3 million to $10.8 million, aligning with its broader 2026 guidance of $43 million to $46 million. The company attributed the outlook to expanded Medicare access under a new Part B benefit category with HCPCS codes for its MyoPro device.
The 2026 revenue range remains unchanged from prior guidance, reflecting confidence in reimbursement-driven demand. Myomo estimates the new Medicare coverage opens access to tens of millions of beneficiaries, removing prior barriers to adoption.
Management did not disclose immediate market reactions during the earnings call.